Course Director

Roy Fleischmann, MD, MACR
Roy Fleischmann, MD, MACR

Metroplex Clinical Research Center
University of Texas Southwestern Medical Center
Dallas, Texas

Accredited by

Medical Learning Institute, Inc.

Activity Details

Credit Types:CME / CPE / CE
Credit Amount:0.75 CME/CPE/MOC/ 1.0 CE Credits
Release Date:2017-Mar-29
Expiration Date:2018-Mar-28
Estimated Time for Completion:45 minutes
Registration Required:No
Cost:Free of Charge

Activity Description and Educational Objectives

In this activity, an expert in rheumatology discusses strategies to individualize care for patients with rheumatoid arthritis.

Upon completion of this activity, participants will be able to:
  • Recognize the significant unmet medical needs in patients with rheumatoid arthritis (RA)
  • Evaluate efficacy and safety data related to novel treatment options for RA, with consideration of patients and clinical scenarios likely to derive benefit from such therapeutic modalities
  • Integrate evidence-based recommendations, clinical trial data, real world evidence, and patient preference into the therapeutic decision-making process for RA
  • Treat RA to target in individual patients based on optimal selection and utilization of therapy

Target Audience

This activity has been designed to meet the educational needs of rheumatologists, nurses, pharmacists and other clinicians involved in the management of patients with rheumatoid arthritis.

Nursing Education Purpose Statement

The purpose of this activity is to improve knowledge and competence of nurses concerning the treatment of rheumatoid arthritis.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. A score of 70% or higher is needed to obtain CME/CE/CPE credit. There are no pre-requisites and there is no fee to participate in this activity or to receive CME/CE/CPE credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Enduring Material
Release and Expiration Dates: March 29, 2017 - March 28, 2018
Time to Complete: 45 minutes

Faculty & Disclosure / Conflict of Interest Policy

Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with any commercial interest producing healthcare goods/services to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by Medical Learning Institute, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The associates of Medical Learning Institute, Inc., the accredited provider for this activity, and PVI, PeerView Institute for Medical Education do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CME/CE/CPE activity for any amount during the past 12 months.

Course Director

Roy Fleischmann, MD, MACR
Medical Director
Metroplex Clinical Research Center
Clinical Professor of Medicine
University of Texas Southwestern Medical Center
Dallas, Texas

Roy Fleischmann, MD, MACR, has a financial interest/relationship or affiliation in the form of:
Consultant for AbbVie Inc.; Akros Pharma Inc.; Amgen Inc.; Bristol-Myers Squibb Company; Eli Lilly and Company; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Pfizer Inc.; Samumed, LLC.; Sanofi-aventis U.S. LLC.; and UCB Inc.
Grant/Research Support from Amgen Inc.; Ardea Inc.; AstraZeneca; Bristol-Myers Squibb Company; Celgene Corporation; Eli Lilly and Company; F. Hoffmann-La Roche Ltd; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Samumed, LLC.; Sanofi-aventis U.S. LLC.; and UCB Inc.

Roy Fleischmann, MD, MACR, does intend to discuss either non–FDA-approved or investigational use for the following products/devices: emerging/novel therapeutic options for rheumatoid arthritis.

CME Reviewer

Kaushal Patel, MD
Nephrology Associates of Central PA
Camp Hill, Pennsylvania

Kaushal Patel, MD, has no financial interests/relationships or affiliations in relation to this activity.

Nurse Reviewer

Bobbie Perrin, RN, OCN
Oncology Nurse Navigator
Harrington Cancer Center
Amarillo, Texas

Bobbie Perrin, RN, OCN, has no financial interests/relationships or affiliations in relation to this activity.

CPE Reviewer

Teresa Haile, RPh, MBA
Blue Cross Blue Shield of Kansas City
Kansas City, Missouri

Teresa Haile, RPh, MBA, has no financial interests/relationships or affiliations in relation to this activity.

Medical Director

Kathryn B. Charalambous, PhD
PVI, PeerView Institute for Medical Education

Kathryn B. Charalambous, PhD, has no financial interests/relationships or affiliations in relation to this activity.


The information provided at this CME/CE/CPE activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition. Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines. No bias towards or promotion for any agent discussed in this program should be inferred.

Providership, Credit & Support

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians.

The Medical Learning Institute, Inc. designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ACPE Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Medical Learning Institute, Inc.
Provider approved by the California Board of Registered Nursing, Provider Number 15106, for 1.0 contact hour(s).

ACPE The Medical Learning Institute, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Completion of this knowledge-based activity provides for 0.75 contact hours (0.075 CEUs) of continuing pharmacy education credit. The Universal Activity Number for this activity is 0468-9999-17-005-H01-P.


This CME/CE/CPE activity is jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education.


This educational activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports.

Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView Press or any of its partners, providers, and/or supporters.

Copyright © 2000-2017, PeerView Press - Medical Education Resource

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.